Ranbaxy Laboratories rallies over 8% on USFDA nod for Diovan’s generic version – Economic Times

Facebook
Economic Times
NEW DELHI: Ranbaxy Laboratories Ltd rallied as much as 8.2 per cent in trade on Friday to hit its fresh 52-week high of Rs 510.45, after the US Food and Drug Administration said on Thursday that it had approved the company’s generic version of Novartis …
India’s Ranbaxy gains; US drug regulator approves generic version of Novartis Reuters UK
Pre-Market: 5 stocks in spotlightBusiness Standard
Sensex Edges Higher, Sun Pharma Rises 4%NDTV

all 20 news articles

…read more

Source: Business News From Google News

Leave a Comment